Evaluation of Inflammatory Activity of Extraocular Muscles in Thyroid Associated Orbitopathy by [Ga]DOTATATE PET/CT

Overview

Journal Mol Imaging Biol

Publisher Springer

Date 2025 Jan 14

PMID 39810068

Authors

Zhengquan Hu

Jinyan Liu

Haoyu Deng

Na Chen

Lu Chen

Sha Wang

Tingting Long

Jia Tan

Shuo Hu

Affiliations

Soon will be listed here.

Abstract

Purpose: The accurate assessment of inflammatory activity of the extraocular muscles (EOMs) in thyroid associated ophthalmopathy (TAO) is crucial for formulating subsequent treatment strategies and prognostic judgments. This study aims to explore the efficacy of using [Ga]DOTATATE PET/CT to assess the inflammatory activity of EOMs in TAO patients.

Procedures: This study enrolled 22 TAO patients and 6 healthy volunteers, all of whom underwent orbital [Ga]DOTATATE PET/CT. Among these, 18 patients underwent orbital [Tc]DTPA SPECT/CT within one week, and the other 4 patients received orbital MRI. All imaging data were independently assessed, followed by comparative data analysis. The patients then received different treatment schemes, and their prognosis was followed up.

Results: [Ga]DOTATATE PET/CT could effectively evaluate the inflammatory activity of the EOMs in TAO patients and demonstrate good consistency with [Tc]DTPA SPECT/CT and orbital MRI, but show a better resolution to distinguish EOMs and surrounding structure. The receiver operating characteristic (ROC) curves for each EOM, treated as individual research units, exhibited an area under the curve (AUC) exceeding 0.9. The medial rectus demonstrated the highest involvement and diagnostic accuracy(AUC = 0.976, P < 0.001). Patients treated with glucocorticoids showed significantly higher SUVmax in EOMs compared to those receiving symptomatic treatment (P < 0.01).

Conclusions: [Ga]DOTATATE PET/CT is a reliable method for assessing the inflammatory activity of EOMs in TAO patients, providing strong objective evidence for the precise diagnosis and treatment.

References

Bartalena L, Baldeschi L, Boboridis K, Eckstein A, Kahaly G, Marcocci C . The 2016 European Thyroid Association/European Group on Graves' Orbitopathy Guidelines for the Management of Graves' Orbitopathy. Eur Thyroid J. 2016; 5(1):9-26. PMC: 4836120. DOI: 10.1159/000443828. View

Bartalena L, Tanda M . Current concepts regarding Graves' orbitopathy. J Intern Med. 2022; 292(5):692-716. PMC: 9796560. DOI: 10.1111/joim.13524. View

Taylor P, Zhang L, Lee R, Muller I, Ezra D, Dayan C . New insights into the pathogenesis and nonsurgical management of Graves orbitopathy. Nat Rev Endocrinol. 2020; 16(2):104-116. DOI: 10.1038/s41574-019-0305-4. View

Bartalena L, Baldeschi L, Dickinson A, Eckstein A, Kendall-Taylor P, Marcocci C . Consensus statement of the European Group on Graves' orbitopathy (EUGOGO) on management of GO. Eur J Endocrinol. 2008; 158(3):273-85. DOI: 10.1530/EJE-07-0666. View

Wang Y, Zhang S, Zhang Y, Liu X, Gu H, Zhong S . A single-center retrospective study of factors related to the effects of intravenous glucocorticoid therapy in moderate-to-severe and active thyroid-associated ophthalmopathy. BMC Endocr Disord. 2018; 18(1):13. PMC: 5819263. DOI: 10.1186/s12902-018-0240-8. View

civrny J, Karhanova M, Hubnerova P, Schovanek J, Herman M . MRI in the assessment of thyroid-associated orbitopathy activity. Clin Radiol. 2022; 77(12):925-934. DOI: 10.1016/j.crad.2022.08.124. View

Ma R, Geng Y, Gan L, Peng Z, Cheng J, Guo J . Quantitative T1 mapping MRI for the assessment of extraocular muscle fibrosis in thyroid-associated ophthalmopathy. Endocrine. 2021; 75(2):456-464. DOI: 10.1007/s12020-021-02873-0. View

Kilicarslan R, Alkan A, Ilhan M, Yetis H, Aralasmak A, Tasan E . Graves' ophthalmopathy: the role of diffusion-weighted imaging in detecting involvement of extraocular muscles in early period of disease. Br J Radiol. 2014; 88(1047):20140677. PMC: 5481836. DOI: 10.1259/bjr.20140677. View

Dodds N, Atcha A, Birchall D, Jackson A . Use of high-resolution MRI of the optic nerve in Graves' ophthalmopathy. Br J Radiol. 2009; 82(979):541-4. DOI: 10.1259/bjr/56958444. View

10.

Kahaly G . Imaging in thyroid-associated orbitopathy. Eur J Endocrinol. 2001; 145(2):107-18. DOI: 10.1530/eje.0.1450107. View

11.

Ujhelyi B, Erdei A, Galuska L, Varga J, Szabados L, Balazs E . Retrobulbar 99mTc-diethylenetriamine-pentaacetic-acid uptake may predict the effectiveness of immunosuppressive therapy in Graves' ophthalmopathy. Thyroid. 2009; 19(4):375-80. DOI: 10.1089/thy.2008.0298. View

12.

Jiang C, Deng Z, Huang J, Deng H, Tan J, Li X . Monitoring and Predicting Treatment Response of Extraocular Muscles in Grave's Orbitopathy by Tc-DTPA SPECT/CT. Front Med (Lausanne). 2022; 8:791131. PMC: 8716578. DOI: 10.3389/fmed.2021.791131. View

13.

Liu D, Xu X, Wang S, Jiang C, Li X, Tan J . 99mTc-DTPA SPECT/CT provided guide on triamcinolone therapy in Graves' ophthalmopathy patients. Int Ophthalmol. 2019; 40(3):553-561. DOI: 10.1007/s10792-019-01213-6. View

14.

Tang M, Zeng X, Li Y, Sun H, Liu S, Yuan X . [The application of Tc-DTPA orbital SPECT/CT in staging evaluation of thyroid associated ophthalmopathy]. Zhonghua Yan Ke Za Zhi. 2021; 57(11):830-836. DOI: 10.3760/cma.j.cn112142-20210331-00152. View

15.

Pasquali D, Notaro A, Bonavolonta G, Vassallo P, Bellastella A, Sinisi A . Somatostatin receptor genes are expressed in lymphocytes from retroorbital tissues in Graves' disease. J Clin Endocrinol Metab. 2002; 87(11):5125-9. DOI: 10.1210/jc.2002-020790. View

16.

Cozma I, Zhang L, Uddin J, Lane C, Rees A, Ludgate M . Modulation of expression of somatostatin receptor subtypes in Graves' ophthalmopathy orbits: relevance to novel analogs. Am J Physiol Endocrinol Metab. 2007; 293(6):E1630-5. DOI: 10.1152/ajpendo.00177.2007. View

17.

Sun H, Jiang X, Wang S, Chen H, Sun J, Li P . (99m)Tc-HYNIC-TOC scintigraphy in evaluation of active Graves' ophthalmopathy (GO). Endocrine. 2007; 31(3):305-10. DOI: 10.1007/s12020-007-0039-2. View

18.

Zhao R, Wang J, Deng J, Yang W, Wang J . Efficacy of (99m)Tc-EDDA/HYNIC-TOC SPECT/CT scintigraphy in Graves' ophthalmopathy. Am J Nucl Med Mol Imaging. 2012; 2(2):242-7. PMC: 3477727. View

19.

Burggasser G, Hurtl I, Hauff W, Lukas J, Greifeneder M, Heydari B . Orbital scintigraphy with the somatostatin receptor tracer 99mTc-P829 in patients with Graves' disease. J Nucl Med. 2003; 44(10):1547-55. View

20.

Fortunati E, Argalia G, Zanoni L, Fanti S, Ambrosini V . New PET Radiotracers for the Imaging of Neuroendocrine Neoplasms. Curr Treat Options Oncol. 2022; 23(5):703-720. PMC: 9001579. DOI: 10.1007/s11864-022-00967-z. View